Biocardia Financial Statements From 2010 to 2022

BCDA
 Stock
  

USD 1.49  0.04  2.76%   

Biocardia financial statements provide useful quarterly and yearly information to potential Biocardia investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Biocardia financial statements helps investors assess Biocardia's valuation, profitability, and current liquidity needs.
We have found seventy-nine available fundamental signals for Biocardia, which can be analyzed and compared to other ratios and to its rivals. Make sure you validate all of Biocardia prevailing market performance against the performance between 2010 and 2022 to make sure the company can sustain itself down the road.
Biocardia Enterprise Value is projected to increase significantly based on the last few years of reporting. The past year's Enterprise Value was at 17 Million. The current year Invested Capital is expected to grow to about 1.1 M, whereas Average Assets are forecasted to decline to about 17.6 M.
  
Check Biocardia financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biocardia main balance sheet or income statement drivers, such as Cost of Revenue of 3.7 K, Gross Profit of 1.1 M or Interest Expense of 2.8 K, as well as many exotic indicators such as Asset Turnover of 0.0518, Book Value per Share of 0.63 or Current Ratio of 3.73. Biocardia financial statements analysis is a perfect complement when working with Biocardia Valuation or Volatility modules. It can also supplement Biocardia's financial leverage analysis and stock options assessment as well as various Biocardia Technical models . Continue to the analysis of Biocardia Correlation against competitors.

Biocardia Revenues

809,105

Biocardia Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets16 M15.7 M13.6 M
Increasing
Stable
Cash and Equivalents12 M12.9 M12.5 M
Decreasing
Very volatile
Deferred Revenue686.8 K847 K313.1 K
Increasing
Slightly volatile
Property Plant and Equipment Net2.2 M2.1 M582.8 K
Increasing
Slightly volatile
Inventory3.7 K3.6 K387.4 K
Decreasing
Slightly volatile
Trade and Non Trade Receivables204.8 K147 K181.1 K
Increasing
Slightly volatile
Trade and Non Trade Payables565.1 K507 K537.5 K
Increasing
Slightly volatile
Total Liabilities4.4 M5.3 M2.7 M
Increasing
Slightly volatile
Shareholders Equity9.9 M10.4 M10.8 M
Decreasing
Stable
Current Assets14.6 M13.5 M13.1 M
Increasing
Very volatile
Assets Non Current2.4 M2.2 M650.9 K
Increasing
Slightly volatile
Current Liabilities3.4 M3.7 M2.4 M
Increasing
Slightly volatile
Liabilities Non CurrentM1.9 M568.1 K
Increasing
Slightly volatile
Total Debt2.1 M1.9 M3.8 M
Decreasing
Slightly volatile
Debt Current243.2 K237 K3.3 M
Decreasing
Slightly volatile
Debt Non Current1.6 M1.9 M868 K
Increasing
Slightly volatile
Shareholders Equity USD9.9 M10.4 M10.8 M
Decreasing
Stable
Cash and Equivalents USD12 M12.9 M12.5 M
Decreasing
Very volatile
Total Debt USD2.1 M1.9 M3.8 M
Decreasing
Slightly volatile

Biocardia Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues809.1 KM464.9 K
Increasing
Slightly volatile
Cost of Revenue3.7 K3.6 K668.3 K
Decreasing
Slightly volatile
Selling General and Administrative Expense4.7 M5.1 M3.4 M
Increasing
Slightly volatile
Research and Development Expense8.3 M8.6 M4.8 M
Increasing
Slightly volatile
Operating Expenses11.6 M13.6 M7.4 M
Increasing
Slightly volatile
Interest Expense2.8 K2.7 K588.7 K
Decreasing
Slightly volatile
Consolidated Income(13 M)(12.6 M)(6.1 M)
Decreasing
Slightly volatile
Net Income(13 M)(12.6 M)(6.1 M)
Decreasing
Slightly volatile
Net Income Common Stock(13 M)(12.6 M)(6.1 M)
Decreasing
Slightly volatile
Weighted Average Shares18.3 M16.9 M5.5 M
Increasing
Slightly volatile
Weighted Average Shares Diluted18.3 M16.9 M5.5 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT(13 M)(12.6 M)(5.8 M)
Decreasing
Slightly volatile
Revenues USD809.1 KM464.9 K
Increasing
Slightly volatile
Net Income Common Stock USD(13 M)(12.6 M)(6.1 M)
Decreasing
Slightly volatile
Earning Before Interest and Taxes USD(13 M)(12.6 M)(5.8 M)
Decreasing
Slightly volatile
Gross Profit1.1 MM227.2 K
Increasing
Slightly volatile
Operating Income(13 M)(12.6 M)(7.4 M)
Decreasing
Slightly volatile

Biocardia Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Business Acquisitions and Disposals22 M21.9 M19.2 M
Increasing
Slightly volatile
Net Cash Flow from FinancingM1.9 M6.1 M
Increasing
Stable
Issuance Repayment of Debt Securities 467.4 K455.4 K2.8 M
Decreasing
Slightly volatile
Issuance Purchase of Equity SharesM1.9 M3.5 M
Increasing
Slightly volatile
Net Cash Flow from Investing(119.1 K)(116 K)3.9 M
Decreasing
Slightly volatile
Net Cash Flow from Operations(10.6 M)(10.4 M)(6.3 M)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(8.8 M)(8.5 M)2.1 M
Decreasing
Slightly volatile
Share Based Compensation1.7 M1.7 M1.2 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion61.6 K60 K94.4 K
Increasing
Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share(0.81)(0.75)(12.977)
Increasing
Slightly volatile
Earnings per Diluted Share(0.81)(0.75)(12.977)
Increasing
Slightly volatile
Earnings per Basic Share USD(0.81)(0.75)(12.977)
Increasing
Slightly volatile
Return on Average Equity(0.94)(0.87)(1.2651)
Decreasing
Slightly volatile
Return on Average Assets(0.71)(0.659)(0.5325)
Decreasing
Slightly volatile
Return on Invested Capital8.187.96524.533
Increasing
Very volatile
Gross Margin1.081.00.6008
Decreasing
Very volatile
Profit Margin(12.07)(11.19)(8.8017)
Decreasing
Slightly volatile
EBITDA Margin(12.02)(11.14)(8.3351)
Decreasing
Slightly volatile
Return on Sales(12.76)(12.436)108
Decreasing
Slightly volatile
Asset Turnover0.05180.0530.039
Increasing
Slightly volatile
Enterprise Value over EBITDA(1.39)(1.353)21.7474
Decreasing
Stable
Enterprise Value over EBIT(1.03)(1.0)22.3057
Decreasing
Stable
Price to Earnings Ratio(2.79)(2.587)(2.1151)
Decreasing
Slightly volatile
Sales per Share0.06160.060.517
Decreasing
Very volatile
Price to Sales Ratio33.1932.335294
Decreasing
Slightly volatile
Price to Book Value4.193.1554.1036
Increasing
Slightly volatile
Debt to Equity Ratio0.560.515(0.0149)
Increasing
Slightly volatile
Current Ratio3.733.6321.2 K
Decreasing
Stable
Free Cash Flow per Share(0.67)(0.62)(4.5481)
Increasing
Very volatile
Book Value per Share0.630.6133.1039
Decreasing
Stable
Tangible Assets Book Value per Share0.950.9297.2132
Decreasing
Stable

Biocardia Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax(13 M)(12.6 M)(6.1 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(12.9 M)(12.6 M)(5.7 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD(12.9 M)(12.6 M)(5.7 M)
Decreasing
Slightly volatile
Market Capitalization47.5 M32.7 M49.2 M
Increasing
Stable
Enterprise Value17.5 M17 M35.5 M
Increasing
Stable
Invested Capital1.1 MM(415.4 K)
Increasing
Stable
Average Equity12.2 M14.5 M11 M
Decreasing
Stable
Average Assets17.6 M19.1 M13.3 M
Increasing
Stable
Invested Capital Average(1.6 M)(1.6 M)(432.3 K)
Decreasing
Slightly volatile
Tangible Asset Value16 M15.7 M13.6 M
Increasing
Stable
Free Cash Flow(10.8 M)(10.5 M)(6.3 M)
Decreasing
Slightly volatile
Working Capital9.5 M9.8 M10.6 M
Decreasing
Stable

Biocardia Fundamental Market Drivers

Short Percent Of Float0.55%
Forward Price Earnings-1.89
Shares Short Prior Month218.14k
Average Daily Volume Last 10 Day19.33k
Average Daily Volume In Three Month50.6k
Date Short Interest15th of July 2022
Fifty Day Average1.5244
Two Hundred Day Average1.9177

Biocardia Upcoming Events

Upcoming Quarterly Report29th of March 2022
Next Financial Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Biocardia Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Biocardia income statement, its balance sheet, and the statement of cash flows. Biocardia investors use historical funamental indicators, such as Biocardia's revenue or net income, to determine how well the company is positioned to perform in the future. Although Biocardia investors may use each financial statement separately, they are all related. The changes in Biocardia's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Biocardia's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Biocardia Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Biocardia. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue847 K686.8 K
Cost of Revenue3.6 K3.7 K
RevenuesM809.1 K
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Biocardia without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module

Pair Trading with Biocardia

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biocardia position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biocardia will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Biocardia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biocardia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biocardia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biocardia to buy it.
The correlation of Biocardia is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biocardia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biocardia moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biocardia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Biocardia Correlation against competitors. Note that the Biocardia information on this page should be used as a complementary analysis to other Biocardia's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Biocardia Stock analysis

When running Biocardia price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Is Biocardia's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
26.1 M
Quarterly Revenue Growth YOY
0.3
Return On Assets
-0.45
Return On Equity
-1.0
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine Biocardia value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.